Zobrazeno 1 - 10
of 267
pro vyhledávání: '"Martina Burlando"'
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2645-2652 (2024)
Abstract Introduction The efficacy and safety of tildrakizumab for the treatment of plaque psoriasis were demonstrated by randomized clinical studies, but the reappraisal of prolonged experiences in the clinical practice helps to optimize the use of
Externí odkaz:
https://doaj.org/article/b428056128db4741bbf3c2c6950d88a8
Autor:
Mario Valenti, Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Diego Orsini, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1649-1657 (2024)
Abstract Introduction The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safet
Externí odkaz:
https://doaj.org/article/2457ce851f3b4d589b890cf51ca53d3c
Autor:
Sarah Alulis, Nicoletta Bernardini, Martina Burlando, Antonio Costanzo, Pier Cesare Francesa Morel, Paolo Gisondi, Francesco Loconsole, Matteo Megna, Giovanni Pellacani, Stefano Piaserico, Francesca Prignano, Ottavio Secchi, Nevena Skroza, Fareen Hassan
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 5, Pp 1273-1291 (2024)
Abstract Introduction There are several treatment options for plaque psoriasis (PsO), but uncertainty remains around the optimal sequencing of treatments. The aims of this study were to investigate how adopting a best-treatment-first treatment sequen
Externí odkaz:
https://doaj.org/article/ff75665eae034ad7a5181488eb2829bc
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Externí odkaz:
https://doaj.org/article/7d26cfef736148cb8d21e50168898a29
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Immune-mediated comorbidities in patients with psoriasiform eczema are common. It can be challenging to manage multiple immune-mediated diseases, especially considering that biologic treatments are prone to causing paradoxical effects. The aim of thi
Externí odkaz:
https://doaj.org/article/b8d3eba042304c269aa6ee5c36f3ec8a
Autor:
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Pina Brianti, Giovanna Brunasso, Martina Burlando, Anna E. Cagni, Marzia Caproni, Carlo G. Carrera, Andrea Carugno, Francesco Caudullo, Aldo Cuccia, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Francesca M. Gaiani, Paolo Gisondi, Claudio Guarneri, Claudia Lasagni, Gaetano Licata, Francesco Loconsole, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Maria L. Musumeci, Diego Orsini, Simone Ribero, Valentina Ruffo Di Calabria, Francesca Satolli, Davide Strippoli, Massimo Travaglini, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractPurpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildra
Externí odkaz:
https://doaj.org/article/50011e4f4d42477e96cf16f9d602b59b
Autor:
Anna Balato, Francesca Ambrogio, Martina Burlando, Carlo Giovanni Carrera, Andrea Chiricozzi, Maria Esposito, Stefano Piaserico, Miriam Teoli, Paolo Gisondi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 1, Pp 5-13 (2023)
Externí odkaz:
https://doaj.org/article/47d2afcf1e714ff893cbd91f46ffd377
Autor:
Diego Orsini, Piergiorgio Malagoli, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Valentina Dini, Maria Esposito, Maria C. Fargnoli, Francesca M. Gaiani, Luigi Gargiulo, Paolo Gisondi, Alessandro Giunta, Luciano Ibba, Claudia Lasagni, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Alessandra Narcisi, Annamaria Offidani, Giovanni Paolino, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Chiara Assorgi, Antonio Costanzo
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 2 (2024)
Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis,
Externí odkaz:
https://doaj.org/article/59fd209fd8eb441cabd179657001da3a
Autor:
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
IntroductionThe development of several effective biological drugs for moderate-to-severe plaque psoriasis has dramatically changed the lives of patients. Despite the wide use of interleukin (IL) inhibitors, limited data are available to date regardin
Externí odkaz:
https://doaj.org/article/e8adfd5931624f3f9e09c85cb9c18c40
Autor:
Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Antonio Cristaudo, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Francesca M. Gaiani, Paolo Gisondi, Alessandro Giunta, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Annamaria Offidani, Diego Orsini, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Piergiorgio Malagoli, Antonio Costanzo
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
IntroductionBimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is
Externí odkaz:
https://doaj.org/article/a57a586330ad40f1847d355dbee4ceef